is it time to buy more or sell, page-6

Orabanda i reckon HCV trial would not only have to fail but fail badly ie: kill someone, which is highly unlikely given the due diligence taken to get FDA approval.

A first pass 'fail' may just mean a re-tweak of the RNAi cassette design, then away they go. 50% of your learning always comes from the first effort.

And even then, other irons in the fire such as the Calimmune HIV, pain and lung cancer programmes are not going to trip on the same detail as HCV (if the worst case happened). De-risked downside, but as for upside - $4, $20?? who knows. Just stand back when she blows.